Dup15q Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Dup15q Syndrome Market Outlook

Thelansis’s “Dup15q Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dup15q Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dup15q Syndrome Overview

Duplication syndrome on chromosome 15q11.2-13.1, also known as Dup15q Syndrome, results from extra genetic material in the 15q11.2-13.1 region, sometimes referred to as the Prader-Willi/Angelman critical region (PWACR). This syndrome is clinically identifiable and is characterized by symptoms such as hypotonia, motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy, including infantile spasms. In rare cases, maternal Dup15q may also lead to psychosis or unexplained death. Approximately 30 percent of individuals with Dup15q Syndrome have strabismus (crossed eyes), and about 20-30 percent experience growth-related issues resulting in smaller stature. Hypotonia tends to improve with age, and in some cases, it may progress to hypertonia, especially in the lower legs. Other associated problems include reduced pain sensitivity, scoliosis, recurrent childhood respiratory infections, precocious puberty, menstrual irregularities in females, minor genital abnormalities in males, overeating, and excessive weight gain.

• The prevalence of Dup15q Syndrome remains uncertain but may affect as many as 1 in 5,000 individuals in the general population and is believed to be roughly ten times more common in people with ASD or intellectual disability.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: